Cytosorbents (CTSO) 10-Q 2021 Q1 Quarterly report

Exhibit 32.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Phillip Chan, Chief Executive Officer of CytoSorbents Corporation, hereby certify, that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the quarter ending March 31, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in such Quarterly Report on Form 10-Q for the quarter ending March 31, 2021, fairly presents, in all material respects, the financial condition and results of operations of CytoSorbents Corporation.

Date:	May 4, 2021
CYTOSORBENTS CORPORATION
By:	/s/ Phillip P. Chan
Phillip Chan Chief Executive Officer